These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 32853086)

  • 1. Therapeutic strategies for Parkinson's disease: promising agents in early clinical development.
    Fabbri M; Perez-Lloret S; Rascol O
    Expert Opin Investig Drugs; 2020 Nov; 29(11):1249-1267. PubMed ID: 32853086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson's disease.
    Perez-Lloret S; Otero-Losada M; Toblli JE; Capani F
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1163-1173. PubMed ID: 28836869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent developments in the pharmacological treatment of Parkinson's disease.
    Tuite P; Riss J
    Expert Opin Investig Drugs; 2003 Aug; 12(8):1335-52. PubMed ID: 12882620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson's disease.
    Carta AR; Simuni T
    Expert Opin Investig Drugs; 2015 Feb; 24(2):219-27. PubMed ID: 25227476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Rasagiline in monotherapy in patients with early stages of Parkinson's disease and in combined and adjunct therapy to levodopa with moderate and advanced stages].
    Pagonabarraga J; Rodríguez-Oroz MC
    Rev Neurol; 2013 Jan; 56(1):25-34. PubMed ID: 23250679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New and emerging medical therapies in Parkinson's disease.
    Lotia M; Jankovic J
    Expert Opin Pharmacother; 2016; 17(7):895-909. PubMed ID: 26830844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease-modifying drugs and Parkinson's disease.
    Allain H; Bentué-Ferrer D; Akwa Y
    Prog Neurobiol; 2008 Jan; 84(1):25-39. PubMed ID: 18037225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-Dopaminergic Treatments for Motor Control in Parkinson's Disease: An Update.
    Gonzalez-Latapi P; Bhowmick SS; Saranza G; Fox SH
    CNS Drugs; 2020 Oct; 34(10):1025-1044. PubMed ID: 32785890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can therapeutic strategies prevent and manage dyskinesia in Parkinson's disease? An update.
    Leta V; Jenner P; Chaudhuri KR; Antonini A
    Expert Opin Drug Saf; 2019 Dec; 18(12):1203-1218. PubMed ID: 31619083
    [No Abstract]   [Full Text] [Related]  

  • 11. New treatments for the motor symptoms of Parkinson's disease.
    Vijverman AC; Fox SH
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):761-77. PubMed ID: 25318835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A neoteric annotation on the advances in combination therapy for Parkinson's disease: nanocarrier-based combination approach and future anticipation. Part II: nanocarrier design and development in focus.
    Unnithan D; Sartaj A; Iqubal MK; Ali J; Baboota S
    Expert Opin Drug Deliv; 2024 Mar; 21(3):437-456. PubMed ID: 38507231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigational α-synuclein aggregation inhibitors: hope for Parkinson's disease.
    Török N; Majláth Z; Szalárdy L; Vécsei L
    Expert Opin Investig Drugs; 2016 Nov; 25(11):1281-1294. PubMed ID: 27677932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rational drug discovery design approaches for treating Parkinson's disease.
    Van der Schyf CJ
    Expert Opin Drug Discov; 2015 Jul; 10(7):713-41. PubMed ID: 26054694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects.
    Schapira AH
    CNS Drugs; 2011 Dec; 25(12):1061-71. PubMed ID: 22133327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-dopaminergic treatments in development for Parkinson's disease.
    Fox SH; Brotchie JM; Lang AE
    Lancet Neurol; 2008 Oct; 7(10):927-38. PubMed ID: 18848312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2024 Update.
    McFarthing K; Buff S; Rafaloff G; Pitzer K; Fiske B; Navangul A; Beissert K; Pilcicka A; Fuest R; Wyse RK; Stott SRW
    J Parkinsons Dis; 2024; 14(5):899-912. PubMed ID: 39031388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Benefits of Therapeutic Interventions Targeting Mitochondria in Parkinson's Disease Patients.
    Ciocca M; Pizzamiglio C
    CNS Neurol Disord Drug Targets; 2024; 23(5):554-561. PubMed ID: 37005519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current and experimental treatments of Parkinson disease: A guide for neuroscientists.
    Oertel W; Schulz JB
    J Neurochem; 2016 Oct; 139 Suppl 1():325-337. PubMed ID: 27577098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological therapy of Parkinson's disease: current options and new avenues.
    Simola N; Pinna A; Fenu S
    Recent Pat CNS Drug Discov; 2010 Nov; 5(3):221-38. PubMed ID: 20726838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.